Home>Topics>Stocks>Regeneron Pharmaceuticals

Regeneron Pharmaceuticals REGN

  1. All
  2. Commentary
  3. Stock Reports
  4. Fund Reports
  5. ETF Reports
  6. Headlines
    1. EC approves Eylea label expansion

      Headlines

      Mon, 11 Aug 2014

      The European Commission approves Regeneron Pharmaceuticals ' (NASDAQ: REGN ) Eylea (aflibercept) for the treatment of visual impairment caused by diabetic macular edema (DME). The new indication complements

    2. The Case That Regeneron May Be Significantly Undervalued

      Headlines

      Fri, 8 Aug 2014

      investors, but appearances may be deceiving. Regeneron Pharmaceuticals , Inc. (NASDAQ: REGN ) is in my view that sort of stock. Its market ..... a few years hence. This article evaluates REGN using a sum-of-the-parts type of analysis

    3. Regeneron Pharmaceuticals' ( REGN ) CEO Leonard Schleifer on Q2 2014 Results - Earnings Call Transcript

      Headlines

      Tue, 5 Aug 2014

      Regeneron Pharmaceuticals (NASDAQ: REGN ) Q2 2014 Earnings Call August 05, 2014 8:30 am ET Executives Michael Aberman - Vice President of Strategy & Investor Relations

    4. New Morningstar Analyst Report for Regeneron Pharmaceuticals Inc

      Stock Reports

      Tue, 5 Aug 2014

      million, and chief scientific officer, George Yancopoulos, received a staggering $81.6 million in 2012. Regeneron Pharmaceuticals discovers, develops, and commercializes products that fight eye disease, cancer and inflammation. The

    5. Regeneron Pharmaceuticals ( REGN ) Q2 2014 Results - Earnings Call Webcast

      Headlines

      Tue, 5 Aug 2014

      The following audio is from a conference call that will begin on August 05, 2014 at 08:30 AM ET. The audio will stream live while the call is active, and can be replayed upon its completion. Listen now Complete Story »

    6. Regeneron sales top forecast as Eylea delivers

      Headlines

      Tue, 5 Aug 2014

      Aug 5 (Reuters) - Regeneron Pharmaceuticals Inc on Tuesday reported quarterly sales above expectations on surging demand for its Eylea treatment for macular degeneration, the leading cause of blindness in the elderly.

    7. Regeneron Pharmaceuticals beats by $0.18, beats on revenue

      Headlines

      Tue, 5 Aug 2014

      Regeneron Pharmaceuticals (NASDAQ: REGN ): Q2 EPS of $2.47 beats by $0.18 . Revenue of $666M (+45.5% Y/Y) beats by $18.01M . Press Release Post your comment!

    8. Cramer's Mad Money - 4 Charts With Fangs (8/4/14)

      Headlines

      Tue, 5 Aug 2014

      By SA Editor Miriam Metzinger : Stocks discussed on the in-depth session of Jim Cramer's Mad Money TV Program, Monday August 4. 4 Charts with Fangs: Google (NASDAQ: GOOG ), (NASDAQ: GOOGL ), Facebook (NASDAQ: FB ), Amazon (NASDAQ: AMZN ), Netflix (NASDAQ: NFLX ) Cramer discussed with technical ...

    9. Notable earnings before Tuesday's open

      Headlines

      Mon, 4 Aug 2014

      LIN , LPX , MDU , MGM , MMP , MSI , MWW , MZOR , NILE , NNN , [[NTi]], NVDQ , NWN , ODP , OXF , OZM , PMC , PQ , RBA , REGN , RHP , RIGL , RTI , SCMP , SCOR , SMG , SNSS , SPAR , STE , TDG , VMC , VSI , VTG , WLK , WNR , ZBRA , ZTS 2 comments!

    10. Cramer's Lightning Round - 6 Biotech Picks (7/30/14)

      Headlines

      Thu, 31 Jul 2014

      on the Lightning Round segment of Jim Cramer's Mad Money Program, Wednesday July 30. Bullish Calls: Regeneron (NASDAQ: REGN ), Celgene (NASDAQ: CELG ), Biogen Idec (NASDAQ: BIIB ), Gilead (NASDAQ: GILD ), Seattle Genetics (NASDAQ: SGEN

    « Prev12345Next »
    Content Partners